Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals (Nasdaq: MIRM) entered a definitive agreement to acquire Bluejay Therapeutics, gaining worldwide rights to brelovitug, a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations.
The deal consideration is $250M cash + $370M in Mirum stock (priced at $71.2085/share) plus up to $200M in sales‑based cash milestones. Mirum also arranged a private placement to raise ~$200M concurrent with closing. AZURE Phase 3 top‑line data expected 2H 2026 with potential BLA submission and launch in 2027. Closing expected Q1 2026, subject to approvals and customary conditions.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced first patient enrollment in the BLOOM Phase 2 study of oral MRM-3379 for Fragile X syndrome (FXS).
The randomized trial will evaluate safety, tolerability, and potential clinical benefit in males with a confirmed FMR1 mutation. Top-line data are expected in 2027. The company noted preclinical cognitive and behavioral improvements and favorable tolerability in healthy volunteers. Interested participants can find the study under NCT07209462 on clinicaltrials.gov.
Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in two investor conferences the week of December 2, 2025: the 8th Annual Evercore HealthCONx Conference with a company presentation on Tuesday, December 2 at 2:10 p.m. ET, and Citi’s 2025 Global Healthcare Conference on Wednesday, December 3. Investors can access webcast links and additional information via the company’s Investors and Media webpage.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced on November 10, 2025 that its Compensation Committee granted inducement awards to 11 new employees under the 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards consist of 53,500 non-qualified stock options and 27,950 restricted stock units (RSUs). Each option has an exercise price of $69.71, equal to Mirum’s closing price on November 10, 2025. Options vest over four years with 25% vesting at the first anniversary and the remainder vesting monthly over 36 months; RSUs vest over three years with 33% vesting on each anniversary, in each case subject to continued service and the terms of the 2020 Inducement Plan and applicable award agreements.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced multiple presentations at AASLD’s The Liver Meeting®, November 7-11, 2025, in Washington, D.C., highlighting new clinical and real-world data for LIVMARLI (maralixibat) and volixibat.
Key items include an oral presentation on additional VANTAGE trial analyses showing volixibat improvements in fatigue and sleep for adults with primary biliary cholangitis (PBC) on November 10, multiple poster presentations on maralixibat real-world pruritus reduction, genetic testing insights from 856 panel tests, IL-31 and bile acid regulation data, and a Mirum-sponsored PFIC diagnosis and treatment fireside discussion on November 9.
Full abstracts are available on the AASLD website and detailed analyses will be posted on Mirum’s publications page after the conference.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported Q3 2025 total revenue of $133.0 million and updated 2025 revenue guidance to $500–$510 million. Q3 LIVMARLI net sales were $92.2 million (+56% vs Q3 2024); Bile Acid Medicines sales were $40.8 million (+31% vs Q3 2024). Total operating expenses were $130.4 million in Q3 2025, including $24.0 million of non-cash stock-based compensation and amortization. Cash, cash equivalents, and investments were $378.0 million as of September 30, 2025.
Pipeline catalysts: VISTAS (volixibat) enrollment complete with topline data expected in Q2 2026; VANTAGE and EXPAND expected to read out in H1 2027; Phase 2 MRM-3379 in Fragile X initiated. Company hosted a conference call on November 4, 2025.
Mirum Pharmaceuticals (Nasdaq: MIRM) said it will participate in two investor events in November 2025: a company presentation at the 2025 Stifel Healthcare Conference on Tuesday, November 11 at 8:40 a.m. ET and attendance at the J.P. Morgan U.S. Opportunities Forum 2025 on Wednesday, November 12.
Investors can find webcast links and additional information in the Investors and Media section of Mirum’s corporate website.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report third quarter 2025 financial results on November 4, 2025 and host a conference call the same day to discuss results and recent corporate progress.
The call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT on Tuesday, November 4, 2025. Dial-in numbers: US toll-free +1 833 470 1428; International +1 646 844 6383; Access Code: 299722. A live webcast will be available in the Events & Presentations section on Mirum’s website and a replay will be available for 30 days.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement equity awards on October 10, 2025 to eight new employees under its 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee granted non‑qualified stock options to purchase 45,800 shares with an exercise price of $72.71 (Mirum's closing price on October 10, 2025) and 22,850 restricted stock units (RSUs). Options vest over four years (25% at one year, then monthly over 36 months); RSUs vest over three years (33% each anniversary), each subject to continued service and the applicable award agreements.
Mirum Pharmaceuticals (NASDAQ:MIRM) announced the granting of inducement awards to four new employees under its 2020 Inducement Plan. The awards, approved by the Compensation Committee, include non-qualified stock options to purchase 10,820 shares at $74.89 per share and 5,390 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
